Table 3.
Drug-related information of patients with HIV treated at MTUTH in 2020.
| Variable | Category | Cases | Controls | X2 test p-value |
|---|---|---|---|---|
| N (%) | N (%) | |||
| Duration on ART | <73 month | 61 (41.8) | 52 (35.6) | 0.280 |
| ≥73 month | 85 (52.8) | 94 (64.4) | ||
| Cotrimoxazole preventive therapy | Yes | 141 (96.6) | 134 (91.8) | 0.083 |
| No | 5 (3.4) | 12 (8.2) | ||
| Restart after interruption | Yes | 27 (18.5) | 7 (4.8) | 0.001 |
| No | 119 (81.5) | 139 (95.2) | ||
| History of previous exposure to ART | Yes | 3 (2) | 0 (0.00) | 0.082 |
| No | 143 (98) | 146 (100) | ||
| ARV drug dispenses at initiation | 1c = AZT-3TC-NVP | 25 (17.1) | 21 (14.4) | 0.483 |
| 1d = AZT-3TC-EFV | 20 (13.8) | 20 (13.8) | ||
| 1e = TDF-3TC-NVP | 64 (43.8) | 57 (39) | ||
| 1f = TDF-3TC-EFV | 37 (25.3) | 48 (32.8) | ||
| History of side effects | Yes | 101 (69.2) | 95 (65.1) | 0.455 |
| No | 45 (30.8) | 51 (34.9) |